Belite Bio to Present Promising Stargardt Disease Data at Major Eye Conferences

Belite Bio to Present Promising Stargardt Disease Data at Major Eye Conferences

For individuals and families affected by inherited retinal diseases (IRDs), particularly Stargardt disease, news of advancements in potential treatments offers significant hope. Belite Bio is set to present detailed Phase 3 clinical trial data for its investigational drug, tinlarebant, at two prominent ophthalmology conferences this July. This marks a crucial step in bringing a potential new therapy closer to the Stargardt community, which currently lacks approved treatments.

Belite Bio announced that it will deliver oral presentations of its Phase 3 DRAGON trial data for tinlarebant at the International Society for Clinical Electrophysiology of Vision (ISCEV) 2026 Symposium in Sydney and the American Society of Retina Specialists (ASRS) 2026 Annual Meeting in Montréal. These presentations are scheduled to take place in July 2026. The company previously shared topline results from the DRAGON trial, which indicated a statistically significant and clinically meaningful 36% reduction in the growth rate of retinal lesions in patients with Stargardt disease compared to placebo. Other reports noted a 35.7% or 37% reduction in atrophic retinal lesion growth. The DRAGON trial enrolled 104 adolescent subjects across 11 jurisdictions. Tinlarebant works by reducing the accumulation of vitamin A-based toxins (bisretinoids) in the eye, which are implicated in the progression of Stargardt disease.

This development is particularly significant for patients and their families because Stargardt disease is a genetic eye disorder, often diagnosed in childhood, that leads to central vision loss, and currently has no FDA-approved treatments. The investigational drug, tinlarebant, is an oral, once-daily therapy. Belite Bio has already submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant, making it the first Stargardt treatment to reach this stage in the FDA approval process. The FDA has granted tinlarebant several important designations, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug status, which can expedite the review and approval process. A rolling NDA submission to the FDA was completed in the second quarter of 2026, and a 60-day FDA filing review period is underway.

While the presentations at these medical conferences will provide further insights into the trial data, the completion of the NDA submission and the FDA's priority designations suggest a potential path forward for tinlarebant. The IRD community eagerly awaits further updates as this promising candidate progresses through the regulatory process, potentially offering the first approved treatment for Stargardt disease.